Skip to content
Peptigraph home
Shop Peptides50% off*

Semaglutide Benefits: Claims vs What Studies Show

Benefits people claim for Semaglutide, set against what published studies measured, and where no study exists.

Medical review pendingGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human / animal studies
23 / 0
in our evidence file (PubMed search, 2 Oct 2026)
FDA status
Approved (Ozempic, Wegovy, Rybelsus)

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Weight lossHuman RCT evidence, 4 of 411 / 0Body weight change (oral); Body weight change at 7·2 mg; Knee osteoarthritis pain (WOMAC)Evidence for weight loss
Heart healthHuman RCT evidence, 4 of 47 / 0Carotid plaque inflammation; Major cardiovascular events; Cardiovascular death, MI or strokeEvidence for heart health
DiabetesHuman RCT evidence, 4 of 45 / 0Major kidney disease events; Body weight change; Major adverse cardiovascular eventsEvidence for diabetes
Brain healthHuman RCT evidence, 4 of 43 / 0Clinical Dementia Rating-Sum of Boxes; CDR-SB change from baseline; Cognitive deficit and dementiaEvidence for brain health
Liver healthHuman RCT evidence, 4 of 42 / 0Steatohepatitis resolution; Fibrosis reduction; NASH resolutionEvidence for liver health
kidney diseaseHuman RCT evidence, 4 of 42 / 0Albuminuria; Major kidney disease events; Major cardiovascular eventsEvidence for kidney disease
InflammationHuman RCT evidence, 4 of 42 / 0Carotid plaque inflammation; C-reactive proteinEvidence for inflammation
Joint painHuman RCT evidence, 4 of 41 / 0Knee osteoarthritis pain (WOMAC)Evidence for joint pain
DepressionHuman observational evidence, 3 of 42 / 0Neuropsychiatric safety; Depression, anxiety and suicidal behaviorEvidence for depression
AnxietyHuman observational evidence, 3 of 42 / 0Neuropsychiatric safety; Depression, anxiety and suicidal behaviorEvidence for anxiety
Muscle growthReview only0 / 0Lean massEvidence for muscle growth
BodybuildingReview only0 / 0Lean massEvidence for bodybuilding

Strongest study per claim: Weight loss, The New England journal of medicine 2025, PMID 40934115; Heart health, American heart journal 2025, PMID 40345413; Diabetes, The New England journal of medicine 2024, PMID 38785209.

What the studies measured

Semaglutide outcomes in published studies
OutcomeResultStudy typeSource
Clinical Dementia Rating-Sum of BoxesOral semaglutide did not slow clinical progression in early Alzheimer disease; both trials were discontinued for negative outcome.Human RCTn = 3808Lancet 2026, PMID 41865758
CDR-SB change from baselineCDR-SB score worsened by 2·3 and 2·2 with semaglutide vs 2·3 and 2·1 with placebo in the two trials.Human RCTn = 3808Lancet 2026, PMID 41865758
Steatohepatitis resolutionSteatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide vs 34.3% on placebo.Human RCTn = 1197The New England journal of medicine 2025, PMID 40305708
Fibrosis reductionLiver fibrosis was reduced without worsening steatohepatitis in 36.8% on semaglutide vs 22.4% on placebo.Human RCTn = 1197The New England journal of medicine 2025, PMID 40305708
Body weight change (oral)Oral semaglutide changed body weight by -13.6% vs -2.2% with placebo at week 64.Human RCTn = 307The New England journal of medicine 2025, PMID 40934115
Body weight change at 7·2 mgBodyweight changed by -18·7% with 7·2 mg vs -15·6% with 2·4 mg and -3·9% with placebo.Human RCTn = 1407The lancet. Diabetes & endocrinology 2025, PMID 40961952
AlbuminuriaAfter 24 weeks, urinary albumin-to-creatinine ratio was reduced by 52.1% with semaglutide vs placebo.Human RCTn = 101Nature medicine 2025, PMID 39455729
Carotid plaque inflammationNo significant difference between semaglutide and placebo in carotid plaque inflammation at week 26.Human RCTn = 101American heart journal 2025, PMID 40345413
Major kidney disease eventsThe risk of the primary kidney composite was 24% lower with semaglutide (331 vs 410 first events; hazard ratio 0.76).Human RCTn = 3533The New England journal of medicine 2024, PMID 38785209
Major cardiovascular eventsThe risk of major cardiovascular events was 18% lower (hazard ratio 0.82).Human RCTn = 3533The New England journal of medicine 2024, PMID 38785209
Knee osteoarthritis pain (WOMAC)Pain score changed by -41.7 points with semaglutide vs -27.5 with placebo at week 68.Human RCTn = 407The New England journal of medicine 2024, PMID 39476339
Body weightBody weight changed by -13.7% with semaglutide vs -3.2% with placebo.Human RCTn = 407The New England journal of medicine 2024, PMID 39476339
Cardiovascular death, MI or strokeThe primary cardiovascular composite occurred in 6.5% on semaglutide vs 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90).Human RCTn = 17604The New England journal of medicine 2023, PMID 37952131
Symptoms and body weightThe symptom score improved by 16.6 points with semaglutide vs 8.7 with placebo, and body weight changed by -13.3% vs -2.6%.Human RCTn = 529The New England journal of medicine 2023, PMID 37622681
C-reactive proteinC-reactive protein changed by -43.5% with semaglutide vs -7.3% with placebo.Human RCTn = 529The New England journal of medicine 2023, PMID 37622681
Weight change vs liraglutideWeight changed by -15.8% with semaglutide vs -6.4% with liraglutide and -1.9% with placebo.Human controlled trialn = 338JAMA 2022, PMID 35015037
Body weight changeMean body weight changed by -14.9% with semaglutide vs -2.4% with placebo at week 68 (difference -12.4 percentage points).Human RCTn = 1961The New England journal of medicine 2021, PMID 33567185
Weight reduction thresholdsAt week 68, 86.4%, 69.1% and 50.5% on semaglutide lost at least 5%, 10% and 15% of body weight, vs 31.5%, 12.0% and 4.9% on placebo.Human RCTn = 1961The New England journal of medicine 2021, PMID 33567185
Weight maintenanceFrom week 20 to week 68, body weight changed by -7.9% with continued semaglutide vs +6.9% after switching to placebo.Human RCTn = 803JAMA 2021, PMID 33755728
Waist circumference and systolic blood pressureContinued semaglutide improved waist circumference (-9.7 cm) and systolic blood pressure (-3.9 mm Hg) versus placebo.Human RCTn = 803JAMA 2021, PMID 33755728

Showing the first 20 of 38 rows, strongest sources first.

Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “semaglutide[ti] AND (STEP OR "once-weekly semaglutide in adults with overweight or obesity" OR "Semaglutide 2.4 mg") AND randomized controlled trial[pt]”: 136 results. PubMed search on 2 Oct 2026 for “semaglutide[ti] AND (cardiovascular outcomes OR "SELECT" OR "SUSTAIN" OR "PIONEER 6" OR "myocardial infarction")”: 560 results. PubMed search on 2 Oct 2026 for “semaglutide[ti] AND (kidney OR FLOW OR "steatohepatitis" OR ESSENCE OR "heart failure" OR "knee osteoarthritis" OR Alzheimer)”: 590 results. PubMed search on 2 Oct 2026 for “semaglutide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR obesity OR cardiovascular OR HbA1c)”: 361 results.

What the labels say semaglutide is for

The Ozempic label lists type 2 diabetes blood-sugar control as the injection's indication, as an adjunct to diet and exercise.[27]

The Wegovy label ties its cardiovascular indication to adults who already have heart or vascular disease together with obesity or overweight, alongside diet and activity changes.[28]

The dated PubMed count for semaglutide and weight terms is 1978 human-only records and 160 animal records (2026-10-02); a count of papers is not a measure of benefit.

Calculated from goals file our PubMed count ledger; goal weight-loss; peptide semaglutide; query (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND ("weight loss"[tiab] OR "weight reduction"[tiab] OR "body weight"[tiab] OR obes*[tiab] OR overweight[tiab] OR adiposity[tiab] OR "fat mass"[tiab] OR "body fat"[tiab] OR "fat loss"[tiab]); date 2026-10-02; human only 1978; animal 160. Formula: count of PubMed records for the dated query with the stated filter (humans not animals, and animals not humans)

Weight loss: what the trials measured

In a 68-week trial of adults with overweight or obesity, body weight fell 14.9% on semaglutide 2.4 mg against 2.4% on placebo.[12]

After a 20-week run-in, adults who kept taking semaglutide in the STEP 4 trial lost a further 7.9% over weeks 20 to 68, while those switched to placebo regained 6.9%.[13]

The cost side of that result: in the same trial, 4.5% of semaglutide participants stopped treatment for gastrointestinal events, against 0.8% on placebo.[12]

Heart and kidney claims, trial by trial

In SELECT, which enrolled adults with heart disease and overweight but no diabetes, a major cardiovascular event occurred in 6.5% on semaglutide and 8.0% on placebo.[9]

In adults with type 2 diabetes at high cardiovascular risk, the primary outcome occurred in 6.6% on semaglutide and 8.9% on placebo.[29]

In people with type 2 diabetes and chronic kidney disease, the risk of a major kidney-disease event was 24% lower on semaglutide than on placebo.[7]

That type 2 diabetes trial also reported more retinopathy complications on semaglutide, a harm that sits beside the heart result.[29]

Claims this page cannot confirm

A PubMed search dated 2026-10-02 for semaglutide with depression, suicide, psychiatric, Alzheimer or cognition terms in the title returned 159 records; this page cites none of them for a mood or memory benefit, so it gives no verdict on those claims.

Calculated from evidence file web/src/data/evidence/semaglutide.json; query semaglutide[tiab] AND (depress*[ti] OR suicid*[ti] OR "psychiatric"[ti] OR Alzheimer*[ti] OR cognit*[ti]); date 2026-10-02; count 159. Formula: count of PubMed records returned by the dated query

A PubMed search dated 2026-10-02 for semaglutide with inflammation, rheumatoid, psoriatic or C-reactive terms returned 60 records; none is quoted here, so no inflammation verdict is given.

Calculated from evidence file web/src/data/evidence/semaglutide.json; query semaglutide[tiab] AND (rheumatoid[tiab] OR "psoriatic"[tiab] OR "inflammation"[ti] OR "C-reactive"[ti]); date 2026-10-02; count 60. Formula: count of PubMed records returned by the dated query

One Alzheimer's programme did report a negative result: both phase 3 trials of oral semaglutide in early Alzheimer's disease were discontinued due to negative clinical outcome.[1]

More on Semaglutide

DosageSide effectsResultsHow it works

Common questions

Is Semaglutide proven to work?

The strongest study we summarise for Semaglutide is human rct evidence, among 27 studies. A trial result is not an approval; see the legal status.

What does semaglutide do?

In the Ozempic label's own words, semaglutide lowers fasting and after-meal blood glucose and reduces body weight.[27]

Does semaglutide protect the heart?

The strongest heart evidence quoted here is a randomised trial in adults with established cardiovascular disease and overweight, where semaglutide 2.4 mg was superior to placebo for a composite of cardiovascular death, heart attack or stroke at a mean follow-up of 39.8 months.[9]

More on Semaglutide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.How it worksTarget, mechanism and how long it acts, from the label or studies.OralStudies that gave Semaglutide as pills and capsules, and what is approved.

Sources

  1. 1Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  2. 2Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  3. 3Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  4. 4Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.The lancet. Diabetes & endocrinology · 2025PMID 40961952Accessed 2 Oct 2026
  5. 5Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nature medicine · 2025PMID 39455729Accessed 2 Oct 2026
  6. 6Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
  7. 7Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
  8. 8Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.The New England journal of medicine · 2024PMID 39476339Accessed 2 Oct 2026
  9. 9Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
  10. 10Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2023PMID 37622681Accessed 2 Oct 2026
  11. 11Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA · 2022PMID 35015037Accessed 2 Oct 2026
  12. 12Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  13. 13Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA · 2021PMID 33755728Accessed 2 Oct 2026
  14. 1412-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine · 2024PMID 39764175Accessed 2 Oct 2026
  15. 15A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.Expert opinion on pharmacotherapy · 2024PMID 38629387Accessed 2 Oct 2026
  16. 16PubMed search: semaglutide[ti] AND (STEP OR "once-weekly semaglutide in adults with overweight or obesity" OR "Semaglutide 2.4 mg") AND randomized controlled trial[pt] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: semaglutide[ti] AND (cardiovascular outcomes OR "SELECT" OR "SUSTAIN" OR "PIONEER 6" OR "myocardial infarction") (560 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: semaglutide[ti] AND (kidney OR FLOW OR "steatohepatitis" OR ESSENCE OR "heart failure" OR "knee osteoarthritis" OR Alzheimer) (590 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: semaglutide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR obesity OR cardiovascular OR HbA1c) (361 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: semaglutide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: semaglutide[ti] AND (chronic kidney disease OR "knee osteoarthritis") AND randomized controlled trial[pt] (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: semaglutide[tiab] AND (depress*[ti] OR suicid*[ti] OR "psychiatric"[ti] OR Alzheimer*[ti] OR cognit*[ti]) (159 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  23. 23PubMed search: semaglutide[tiab] AND (blood pressure[ti] OR lipid*[ti] OR cholesterol[ti] OR "visceral"[ti] OR "waist"[ti] OR "body composition"[ti]) (112 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  24. 24PubMed search: semaglutide[tiab] AND (rheumatoid[tiab] OR "psoriatic"[tiab] OR "inflammation"[ti] OR "C-reactive"[ti]) (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  25. 25PubMed search: semaglutide[ti] AND ("knee osteoarthritis" OR "osteoarthritis" OR "obesity-related") AND (pain OR knee) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  26. 26PubMed search: semaglutide[tiab] AND (Alzheimer*[tiab] OR evoke[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  27. 27OZEMPIC prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  28. 28WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  29. 29Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026

Found an error? Report a correction.